Literature DB >> 18025083

ErbB-2 and met reciprocally regulate cellular signaling via plexin-B1.

Jakub M Swiercz1, Thomas Worzfeld, Stefan Offermanns.   

Abstract

Sema4D-induced activation of plexin-B1 has been reported to evoke different and sometimes opposing cellular responses. The mechanisms underlying the versatility of plexin-B1-mediated effects are not clear. Plexin-B1 can associate with the receptor tyrosine kinases ErbB-2 and Met. Here we show that Sema4D-induced activation and inactivation of RhoA require ErbB-2 and Met, respectively. In breast carcinoma cells, Sema4D can have pro- and anti-migratory effects depending on the presence of ErbB-2 and Met, and the exchange of the two receptor tyrosine kinases is sufficient to convert the cellular response to Sema4D from pro- to anti-migratory and vice versa. This work identifies a novel mechanism by which plexin-mediated signaling can be regulated and explains how Sema4D can exert different biological activities through the differential association of its receptor with ErbB-2 and Met.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025083     DOI: 10.1074/jbc.M706822200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Authors:  Paul E Clavijo; Jay Friedman; Yvette Robbins; Ellen C Moore; Ernest Smith; Maurice Zauderer; Elizabeth E Evans; Clint T Allen
Journal:  Cancer Immunol Res       Date:  2018-12-04       Impact factor: 11.151

Review 2.  Semaphorins in angiogenesis and tumor progression.

Authors:  Gera Neufeld; Adi D Sabag; Noa Rabinovicz; Ofra Kessler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  Spatial organization of transmembrane receptor signalling.

Authors:  Ioanna Bethani; Sigrid S Skånland; Ivan Dikic; Amparo Acker-Palmer
Journal:  EMBO J       Date:  2010-08-18       Impact factor: 11.598

Review 4.  Regulation of immune cell responses by semaphorins and their receptors.

Authors:  Hyota Takamatsu; Tatsusada Okuno; Atsushi Kumanogoh
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

Review 5.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

Review 6.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

7.  Suppression of bone formation by osteoclastic expression of semaphorin 4D.

Authors:  Takako Negishi-Koga; Masahiro Shinohara; Noriko Komatsu; Haruhiko Bito; Tatsuhiko Kodama; Roland H Friedel; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

8.  Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential.

Authors:  Sreeharsha Gurrapu; Emanuela Pupo; Giulia Franzolin; Letizia Lanzetti; Luca Tamagnone
Journal:  Cell Death Differ       Date:  2018-03-19       Impact factor: 15.828

Review 9.  Tyrosine phosphorylation in semaphorin signalling: shifting into overdrive.

Authors:  Mélanie Franco; Luca Tamagnone
Journal:  EMBO Rep       Date:  2008-07-25       Impact factor: 8.807

10.  A novel method for the simultaneous enrichment, identification, and quantification of phosphopeptides and sialylated glycopeptides applied to a temporal profile of mouse brain development.

Authors:  Giuseppe Palmisano; Benjamin L Parker; Kasper Engholm-Keller; Sara Eun Lendal; Katarzyna Kulej; Melanie Schulz; Veit Schwämmle; Mark E Graham; Henrik Saxtorph; Stuart J Cordwell; Martin R Larsen
Journal:  Mol Cell Proteomics       Date:  2012-07-26       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.